The US regulator has approved a new single-dose prefilled syringe version of Eylea (aflibercept).

The 2mg syringe provides doctors with a new way to administer the therapy, requiring fewer preparation steps, compared to vials.

Marketed by Regeneron Pharmaceuticals, Eylea is approved in the USA to treat neovascular (wet) age-related macular degeneration (Wet AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME) and diabetic retinopathy (DR).

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *